Palvella Therapeutics, Inc. Stock Issued During Period, Shares, Employee Stock Purchase Plans
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Palvella Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2023 was 154.66K shares, a 14.77% decline from fiscal 2022.
- Palvella Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2022 was 181.47K shares, a 182.41% increase from fiscal 2021.
- Palvella Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2021 was 64.26K shares, a 7.60% decline from fiscal 2020.
- Palvella Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2020 was 69.54K shares, a 38.52% decline from fiscal 2019.
| Period end | Stock Issued During Period, Shares, Employee Stock Purchase Plans 3 month | Stock Issued During Period, Shares, Employee Stock Purchase Plans 12 month |
|---|---|---|
| 2023-12-31 | 154.66K shares 10-K · filed 2024-03-29 | |
| 2022-12-31 | 181.47K shares 10-K · filed 2024-03-29 | |
| 2021-12-31 | 64.26K shares 10-K · filed 2023-03-31 | |
| 2020-12-31 | 69.54K shares 10-K · filed 2022-03-02 | |
| 2019-12-31 | 113.11K shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |